Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) – Equity researchers at Jefferies Financial Group lowered their estimates for first-quarter 2023 earnings per share for Prestige Consumer Healthcare in a research report released Thursday, June 23. Jefferies Financial Group analyst S. Wissink now expects the company to earn $1.03 per share for the quarter, down from its previous forecast of $1.05. Jefferies Financial Group has a “Buy” rating and a price target of $70.00 on the stock. Prestige Consumer Healthcare’s current annual earnings consensus estimate is $4.20 per share. Jefferies Financial Group also released estimates for Q2 2023 earnings of Prestige Consumer Healthcare at $1.04 EPS, Q3 2023 earnings at $1.06 EPS, fiscal year 2023 earnings at $4.18 EPS , Q1 2024 earnings at $1.07 EPS and Q3 2024 earnings at $1.12 EPS. Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last released quarterly earnings data on Thursday, May 5. The company reported earnings per share of $0.91 for the quarter, beating the consensus estimate of $0.89 by $0.02. The company posted revenue of $266.94 million for the quarter, versus $258.25 million expected by analysts. Prestige Consumer Healthcare had a return on equity of 13.82% and a net margin of 18.90%. Prestige Consumer Healthcare revenue for the quarter increased 12.3% year over year. In the same quarter a year earlier, the company posted EPS of $0.79.
A number of other analysts have also weighed in on the company recently. Oppenheimer upgraded Prestige Consumer Healthcare from a “market performance” rating to an “outperform” rating and set a target price of $63.00 for the company in a Monday, May 9 research report. StockNews.com began covering Prestige Consumer Healthcare in a research report on Thursday, March 31. They set a “buy” rating on the stock. Two research analysts rated the stock with a hold rating and three gave the company a buy rating. Based on MarketBeat data, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and a consensus price target of $80.50.
PBH stock opened at $56.67 on Friday. The company’s 50-day simple moving average is $55.20 and its 200-day simple moving average is $56.85. The company has a market capitalization of $2.84 billion, a PE ratio of 14.03, a PEG ratio of 1.65 and a beta of 0.58. Prestige Consumer Healthcare has a 1 year minimum of $50.40 and a 1 year maximum of $63.83. The company has a current ratio of 2.04, a quick ratio of 1.21 and a debt ratio of 0.94.
A number of hedge funds have recently changed their holdings in the company. Mutual of America Capital Management LLC increased its holdings of Prestige Consumer Healthcare shares by 2.5% during the fourth quarter. Mutual of America Capital Management LLC now owns 6,845 shares of the company worth $415,000 after acquiring 170 additional shares during the period. Louisiana State Employees Retirement System increased its stake in shares of Prestige Consumer Healthcare by 0.8% in the 4th quarter. Louisiana State Employees Retirement System now owns 24,300 shares of the company worth $1,474,000 after buying 200 more shares last quarter. Mercer Global Advisors Inc. ADV increased its stake in shares of Prestige Consumer Healthcare by 3.2% in Q1. Mercer Global Advisors Inc. ADV now owns 7,271 shares of the company worth $385,000 after buying 228 additional shares in the last quarter. Great West Life Assurance Co. Can increased its stake in shares of Prestige Consumer Healthcare by 0.6% in Q1. Great West Life Assurance Co. Can now owns 43,488 shares of the company worth $2,362,000 after purchasing an additional 241 shares last quarter. Finally, Maryland State Retirement & Pension System increased its stake in Prestige Consumer Healthcare by 1.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 19,975 shares of the company worth $1,211,000 after buying 278 additional shares in the last quarter.
Company Profile Prestige Consumer Healthcare (Get a rating)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes and sells over-the-counter health and personal care products in the United States and around the world. The Company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Prestige Consumer Healthcare right now?
Before you consider Prestige Consumer Healthcare, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold… and Prestige Consumer Healthcare was not on the list.
While Prestige Consumer Healthcare currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here